ID   GUC2C_HUMAN             Reviewed;        1073 AA.
AC   P25092; B2RMY6;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   12-OCT-2022, entry version 209.
DE   RecName: Full=Guanylyl cyclase C {ECO:0000303|PubMed:11950846};
DE            Short=GC-C {ECO:0000303|PubMed:11950846};
DE            EC=4.6.1.2 {ECO:0000269|PubMed:11950846, ECO:0000269|PubMed:23269669, ECO:0000305|PubMed:1718270};
DE   AltName: Full=Heat-stable enterotoxin receptor {ECO:0000303|PubMed:1718270};
DE            Short=STA receptor {ECO:0000303|PubMed:1718270};
DE            Short=hSTAR {ECO:0000303|PubMed:1718270};
DE   AltName: Full=Intestinal guanylate cyclase;
DE   Flags: Precursor;
GN   Name=GUCY2C {ECO:0000303|PubMed:22521417, ECO:0000312|HGNC:HGNC:4688};
GN   Synonyms=GUC2C, STAR {ECO:0000303|PubMed:1718270};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND VARIANT
RP   LEU-281.
RX   PubMed=1718270; DOI=10.1016/0006-291x(91)91736-v;
RA   Singh S., Singh G., Heim J.-M., Gerzer R.;
RT   "Isolation and expression of a guanylate cyclase-coupled heat stable
RT   enterotoxin receptor cDNA from a human colonic cell line.";
RL   Biochem. Biophys. Res. Commun. 179:1455-1463(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND VARIANT LEU-281.
RX   PubMed=1680854; DOI=10.1016/s0021-9258(18)55214-5;
RA   de Sauvage F.J., Camerato T.R., Goeddel D.V.;
RT   "Primary structure and functional expression of the human receptor for
RT   Escherichia coli heat-stable enterotoxin.";
RL   J. Biol. Chem. 266:17912-17918(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-281.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-281.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-72.
RC   TISSUE=Placenta;
RX   PubMed=8605253; DOI=10.1016/0167-4781(95)00190-5;
RA   Mann E.A., Jump M.L., Giannella R.A.;
RT   "Cell line-specific transcriptional activation of the promoter of the human
RT   guanylyl cyclase C/heat-stable enterotoxin receptor gene.";
RL   Biochim. Biophys. Acta 1305:7-10(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 24-1073, FUNCTION, AND VARIANT
RP   LEU-281.
RC   TISSUE=Colon carcinoma;
RX   PubMed=8381596; DOI=10.1152/ajpgi.1993.264.1.g172;
RA   Mann E.A., Cohen M.B., Giannella R.A.;
RT   "Comparison of receptors for Escherichia coli heat-stable enterotoxin:
RT   novel receptor present in IEC-6 cells.";
RL   Am. J. Physiol. 264:G172-G178(1993).
RN   [8]
RP   SUBUNIT.
RX   PubMed=11123935; DOI=10.1021/bi0013849;
RA   Vijayachandra K., Guruprasad M., Bhandari R., Manjunath U.H., Somesh B.P.,
RA   Srinivasan N., Suguna K., Visweswariah S.S.;
RT   "Biochemical characterization of the intracellular domain of the human
RT   guanylyl cyclase C receptor provides evidence for a catalytically active
RT   homotrimer.";
RL   Biochemistry 39:16075-16083(2000).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH PDZK2.
RX   PubMed=11950846; DOI=10.1074/jbc.m202434200;
RA   Scott R.O., Thelin W.R., Milgram S.L.;
RT   "A novel PDZ protein regulates the activity of guanylyl cyclase C, the
RT   heat-stable enterotoxin receptor.";
RL   J. Biol. Chem. 277:22934-22941(2002).
RN   [10]
RP   GLYCOSYLATION AT ASN-32; ASN-75; ASN-79; ASN-195; ASN-284; ASN-307; ASN-345
RP   AND ASN-402, LACK OF GLYCOSYLATION AT ASN-357, FUNCTION, CATALYTIC
RP   ACTIVITY, INTERACTION WITH VIP36, AND SUBCELLULAR LOCATION.
RX   PubMed=23269669; DOI=10.1074/jbc.m112.413906;
RA   Arshad N., Ballal S., Visweswariah S.S.;
RT   "Site-specific N-linked glycosylation of receptor guanylyl cyclase C
RT   regulates ligand binding, ligand-mediated activation and interaction with
RT   vesicular integral membrane protein 36, VIP36.";
RL   J. Biol. Chem. 288:3907-3917(2013).
RN   [11]
RP   VARIANT MECIL GLY-387, FUNCTION, AND CHARACTERIZATION OF VARIANT MECIL
RP   GLY-387.
RX   PubMed=22521417; DOI=10.1016/j.ajhg.2012.03.022;
RA   Romi H., Cohen I., Landau D., Alkrinawi S., Yerushalmi B., Hershkovitz R.,
RA   Newman-Heiman N., Cutting G.R., Ofir R., Sivan S., Birk O.S.;
RT   "Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating
RT   guanylate cyclase 2C.";
RL   Am. J. Hum. Genet. 90:893-899(2012).
RN   [12]
RP   VARIANT DIAR6 ILE-840, FUNCTION, AND CHARACTERIZATION OF VARIANT DIAR6
RP   ILE-840.
RX   PubMed=22436048; DOI=10.1056/nejmoa1110132;
RA   Fiskerstrand T., Arshad N., Haukanes B.I., Tronstad R.R., Pham K.D.,
RA   Johansson S., Havik B., Tonder S.L., Levy S.E., Brackman D., Boman H.,
RA   Biswas K.H., Apold J., Hovdenak N., Visweswariah S.S., Knappskog P.M.;
RT   "Familial diarrhea syndrome caused by an activating GUCY2C mutation.";
RL   N. Engl. J. Med. 366:1586-1595(2012).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-30; ARG-61; GLN-114; LEU-464; LYS-610;
RP   VAL-859; ARG-1045 AND CYS-1072.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Guanylyl cyclase that catalyzes synthesis of cyclic GMP
CC       (cGMP) from GTP (PubMed:1718270, PubMed:11950846, PubMed:23269669,
CC       PubMed:22521417, PubMed:22436048). Receptor for the E.coli heat-stable
CC       enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of
CC       cGMP in mammalian cells expressing GUCY2C (PubMed:1718270,
CC       PubMed:1680854). Also activated by the endogenous peptides guanylin and
CC       uroguanylin (PubMed:8381596). {ECO:0000269|PubMed:11950846,
CC       ECO:0000269|PubMed:1680854, ECO:0000269|PubMed:1718270,
CC       ECO:0000269|PubMed:22436048, ECO:0000269|PubMed:22521417,
CC       ECO:0000269|PubMed:23269669, ECO:0000269|PubMed:8381596}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP = 3',5'-cyclic GMP + diphosphate; Xref=Rhea:RHEA:13665,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:37565, ChEBI:CHEBI:57746; EC=4.6.1.2;
CC         Evidence={ECO:0000269|PubMed:11950846, ECO:0000269|PubMed:23269669,
CC         ECO:0000305|PubMed:1718270};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13666;
CC         Evidence={ECO:0000269|PubMed:11950846, ECO:0000305|PubMed:1718270};
CC   -!- SUBUNIT: Homotrimer (PubMed:11123935). Interacts via its C-terminal
CC       region with PDZK2 (PubMed:11950846). Interacts with the lectin
CC       chaperone VIP36 (PubMed:23269669). {ECO:0000269|PubMed:11123935,
CC       ECO:0000269|PubMed:11950846, ECO:0000269|PubMed:23269669}.
CC   -!- INTERACTION:
CC       P25092; Q86UT5-2: PDZD3; NbExp=4; IntAct=EBI-2816795, EBI-8299496;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23269669};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:23269669}.
CC       Endoplasmic reticulum membrane {ECO:0000269|PubMed:23269669}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:23269669}. Note=The
CC       145 kDa plasma membrane form of GUCY2C contains sialic acid and
CC       galactose residues, while a differencially glycosylated 130 Kda form is
CC       a high mannose form that is resident in the endoplasmic reticulum and
CC       may serve as the precursor for the cell surface form.
CC       {ECO:0000269|PubMed:23269669}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive.
CC   -!- PTM: Glycosylation at Asn-75 and/or Asn-79 is required for interaction
CC       with VIP36 while glycosylation at Asn-345 and Asn-402 modulates ligand-
CC       mediated GUCY2C activation. {ECO:0000269|PubMed:23269669}.
CC   -!- DISEASE: Diarrhea 6 (DIAR6) [MIM:614616]: A relatively mild, early-
CC       onset chronic diarrhea that may be associated with increased
CC       susceptibility to inflammatory bowel disease, small bowel obstruction,
CC       and esophagitis. {ECO:0000269|PubMed:22436048}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Meconium ileus (MECIL) [MIM:614665]: A condition characterized
CC       by intestinal obstruction due to inspissated meconium in the distal
CC       ileum and cecum, which develops in utero and presents shortly after
CC       birth as a failure to pass meconium. Meconium ileus is a known clinical
CC       manifestation of cystic fibrosis. {ECO:0000269|PubMed:22521417}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the adenylyl cyclase class-4/guanylyl cyclase
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00099}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GUCY2CID43303ch12p13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S57551; AAB19934.2; -; mRNA.
DR   EMBL; M73489; AAA36655.1; -; mRNA.
DR   EMBL; AC007545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010168; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471094; EAW96324.1; -; Genomic_DNA.
DR   EMBL; BC136544; AAI36545.1; -; mRNA.
DR   EMBL; BC136545; AAI36546.1; -; mRNA.
DR   EMBL; U20230; AAC50381.1; -; Genomic_DNA.
DR   CCDS; CCDS8664.1; -.
DR   PIR; A40940; OYHUHX.
DR   RefSeq; NP_004954.2; NM_004963.3.
DR   AlphaFoldDB; P25092; -.
DR   SMR; P25092; -.
DR   BioGRID; 109239; 2.
DR   IntAct; P25092; 3.
DR   MINT; P25092; -.
DR   STRING; 9606.ENSP00000261170; -.
DR   ChEMBL; CHEMBL1795197; -.
DR   DrugBank; DB08890; Linaclotide.
DR   DrugCentral; P25092; -.
DR   GuidetoPHARMACOLOGY; 1750; -.
DR   TCDB; 8.A.85.1.1; the guanylate cyclase (gc) family.
DR   GlyGen; P25092; 8 sites.
DR   iPTMnet; P25092; -.
DR   PhosphoSitePlus; P25092; -.
DR   BioMuta; GUCY2C; -.
DR   DMDM; 311033390; -.
DR   jPOST; P25092; -.
DR   MassIVE; P25092; -.
DR   MaxQB; P25092; -.
DR   PaxDb; P25092; -.
DR   PeptideAtlas; P25092; -.
DR   PRIDE; P25092; -.
DR   ProteomicsDB; 54253; -.
DR   ABCD; P25092; 1 sequenced antibody.
DR   Antibodypedia; 12046; 310 antibodies from 24 providers.
DR   DNASU; 2984; -.
DR   Ensembl; ENST00000261170.5; ENSP00000261170.3; ENSG00000070019.5.
DR   GeneID; 2984; -.
DR   KEGG; hsa:2984; -.
DR   MANE-Select; ENST00000261170.5; ENSP00000261170.3; NM_004963.4; NP_004954.2.
DR   UCSC; uc001rcd.4; human.
DR   CTD; 2984; -.
DR   DisGeNET; 2984; -.
DR   GeneCards; GUCY2C; -.
DR   HGNC; HGNC:4688; GUCY2C.
DR   HPA; ENSG00000070019; Tissue enriched (intestine).
DR   MalaCards; GUCY2C; -.
DR   MIM; 601330; gene.
DR   MIM; 614616; phenotype.
DR   MIM; 614665; phenotype.
DR   neXtProt; NX_P25092; -.
DR   OpenTargets; ENSG00000070019; -.
DR   Orphanet; 314373; Chronic infantile diarrhea due to guanylate cyclase 2C overactivity.
DR   Orphanet; 103908; Congenital sodium diarrhea.
DR   Orphanet; 314376; Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency.
DR   PharmGKB; PA29069; -.
DR   VEuPathDB; HostDB:ENSG00000070019; -.
DR   eggNOG; KOG1023; Eukaryota.
DR   GeneTree; ENSGT00940000155955; -.
DR   HOGENOM; CLU_001072_1_3_1; -.
DR   InParanoid; P25092; -.
DR   OMA; VMCGGPE; -.
DR   OrthoDB; 229634at2759; -.
DR   PhylomeDB; P25092; -.
DR   BRENDA; 4.6.1.2; 2681.
DR   PathwayCommons; P25092; -.
DR   Reactome; R-HSA-8935690; Digestion.
DR   Reactome; R-HSA-8942233; Intestinal infectious diseases.
DR   SignaLink; P25092; -.
DR   SIGNOR; P25092; -.
DR   BioGRID-ORCS; 2984; 6 hits in 1077 CRISPR screens.
DR   ChiTaRS; GUCY2C; human.
DR   GeneWiki; Guanylate_cyclase_2C; -.
DR   GenomeRNAi; 2984; -.
DR   Pharos; P25092; Tclin.
DR   PRO; PR:P25092; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P25092; protein.
DR   Bgee; ENSG00000070019; Expressed in jejunal mucosa and 59 other tissues.
DR   Genevisible; P25092; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004383; F:guanylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:0016941; F:natriuretic peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0001653; F:peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0015643; F:toxic substance binding; IEA:Ensembl.
DR   GO; GO:0006182; P:cGMP biosynthetic process; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd07302; CHD; 1.
DR   CDD; cd14044; PK_GC-C; 1.
DR   Gene3D; 3.30.70.1230; -; 1.
DR   InterPro; IPR001054; A/G_cyclase.
DR   InterPro; IPR018297; A/G_cyclase_CS.
DR   InterPro; IPR042822; GC-C_PK.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR029787; Nucleotide_cyclase.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   Pfam; PF00211; Guanylate_cyc; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   SMART; SM00044; CYCc; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   SUPFAM; SSF55073; SSF55073; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00452; GUANYLATE_CYCLASE_1; 1.
DR   PROSITE; PS50125; GUANYLATE_CYCLASE_2; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; cGMP biosynthesis; Disease variant; Endoplasmic reticulum;
KW   Glycoprotein; GTP-binding; Lyase; Membrane; Nucleotide-binding; Receptor;
KW   Reference proteome; Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..1073
FT                   /note="Guanylyl cyclase C"
FT                   /id="PRO_0000012376"
FT   TOPO_DOM        24..430
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        431..454
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        455..1073
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          489..749
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          824..954
FT                   /note="Guanylate cyclase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00099"
FT   SITE            357
FT                   /note="Not glycosylated"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        195
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        284
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        307
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        345
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   CARBOHYD        402
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23269669"
FT   VARIANT         30
FT                   /note="C -> R (in dbSNP:rs56142849)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042221"
FT   VARIANT         61
FT                   /note="G -> R (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042222"
FT   VARIANT         114
FT                   /note="R -> Q (in dbSNP:rs56275235)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042223"
FT   VARIANT         281
FT                   /note="F -> L (in dbSNP:rs1420635)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1680854, ECO:0000269|PubMed:1718270,
FT                   ECO:0000269|PubMed:8381596, ECO:0000269|Ref.4"
FT                   /id="VAR_049253"
FT   VARIANT         387
FT                   /note="D -> G (in MECIL; activation of guanylate cyclase
FT                   activity is 60% lower than in wild-type;
FT                   dbSNP:rs587776905)"
FT                   /evidence="ECO:0000269|PubMed:22521417"
FT                   /id="VAR_068174"
FT   VARIANT         464
FT                   /note="R -> L (in dbSNP:rs55684775)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042224"
FT   VARIANT         610
FT                   /note="E -> K (in dbSNP:rs55897626)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042225"
FT   VARIANT         840
FT                   /note="S -> I (in DIAR6; activating mutation; exposure of
FT                   the mutant receptor to its ligands results in markedly
FT                   increased production of cyclic guanosine monophosphate;
FT                   dbSNP:rs587776871)"
FT                   /evidence="ECO:0000269|PubMed:22436048"
FT                   /id="VAR_067724"
FT   VARIANT         859
FT                   /note="I -> V (in dbSNP:rs34890806)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042226"
FT   VARIANT         1045
FT                   /note="Q -> R (in dbSNP:rs35617837)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042227"
FT   VARIANT         1072
FT                   /note="Y -> C (in dbSNP:rs35179392)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042228"
FT   CONFLICT        322
FT                   /note="A -> R (in Ref. 1; AAB19934)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        331
FT                   /note="L -> V (in Ref. 1; AAB19934)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        509
FT                   /note="D -> V (in Ref. 1; AAB19934)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        543
FT                   /note="N -> T (in Ref. 1; AAB19934)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1073 AA;  123403 MW;  486A4DE6F9097E22 CRC64;
     MKTLLLDLAL WSLLFQPGWL SFSSQVSQNC HNGSYEISVL MMGNSAFAEP LKNLEDAVNE
     GLEIVRGRLQ NAGLNVTVNA TFMYSDGLIH NSGDCRSSTC EGLDLLRKIS NAQRMGCVLI
     GPSCTYSTFQ MYLDTELSYP MISAGSFGLS CDYKETLTRL MSPARKLMYF LVNFWKTNDL
     PFKTYSWSTS YVYKNGTETE DCFWYLNALE ASVSYFSHEL GFKVVLRQDK EFQDILMDHN
     RKSNVIIMCG GPEFLYKLKG DRAVAEDIVI ILVDLFNDQY FEDNVTAPDY MKNVLVLTLS
     PGNSLLNSSF SRNLSPTKRD FALAYLNGIL LFGHMLKIFL ENGENITTPK FAHAFRNLTF
     EGYDGPVTLD DWGDVDSTMV LLYTSVDTKK YKVLLTYDTH VNKTYPVDMS PTFTWKNSKL
     PNDITGRGPQ ILMIAVFTLT GAVVLLLLVA LLMLRKYRKD YELRQKKWSH IPPENIFPLE
     TNETNHVSLK IDDDKRRDTI QRLRQCKYDK KRVILKDLKH NDGNFTEKQK IELNKLLQID
     YYNLTKFYGT VKLDTMIFGV IEYCERGSLR EVLNDTISYP DGTFMDWEFK ISVLYDIAKG
     MSYLHSSKTE VHGRLKSTNC VVDSRMVVKI TDFGCNSILP PKKDLWTAPE HLRQANISQK
     GDVYSYGIIA QEIILRKETF YTLSCRDRNE KIFRVENSNG MKPFRPDLFL ETAEEKELEV
     YLLVKNCWEE DPEKRPDFKK IETTLAKIFG LFHDQKNESY MDTLIRRLQL YSRNLEHLVE
     ERTQLYKAER DRADRLNFML LPRLVVKSLK EKGFVEPELY EEVTIYFSDI VGFTTICKYS
     TPMEVVDMLN DIYKSFDHIV DHHDVYKVET IGDAYMVASG LPKRNGNRHA IDIAKMALEI
     LSFMGTFELE HLPGLPIWIR IGVHSGPCAA GVVGIKMPRY CLFGDTVNTA SRMESTGLPL
     RIHVSGSTIA ILKRTECQFL YEVRGETYLK GRGNETTYWL TGMKDQKFNL PTPPTVENQQ
     RLQAEFSDMI ANSLQKRQAA GIRSQKPRRV ASYKKGTLEY LQLNTTDKES TYF
//
